RE:RE:RE:Zenith webcastHey canon, you got that right!
One question is how long was enzalutamide on the market as a standard of care drug for mCRPC before Pfizer moved in and bought the company for $14 billion. I have not yet researched this. If anybody has please post it.
I truly wish Don would learn a lesson and become more responsible in has statements. He often makes flippant comments and does not deliver on promises.
So when he stated zen3694 trial results would be available in a couple of months lets all check in mid Feb 2017 to see the results. Unfortunately I am almost certain we will not see results at that time, particularly given that the enzalutamide dosing has just started. I'm still very excited about the potential of zen3694 and the many other compounds/molecules they have in their portfolio.
I'm still betting that there is a higher probability of a pay out of some sort by Zenith long before RVX. However, I don't know if this will be in the form of SF's Star Factories (I hope it is). Don has waffled on his statements and last February he said he was no longer interested in a NASDAQ listing. In Jan/Feb of 2015 he said they were looking for a NASDAQ listing for Zenith to provide liquidity. Since that time Zenith has beeh restructured in to Zenith Inc = ZEN Capital & ZEN Epigenetics. Then, as approved at the AGMs the royality preferred shares (RPS) were restructured (all great news IMHO). Also in Feb 2016 Don said he was looking to purchase a distressed company that has a TSX and/or NASDAQ listing in order to take Zenith public and we have no reported progress on that front.
We pretty much know that with the apabetalone (rvx-208) BETonMACE trial that, based on Don's statement in the Q & A, that a BP suitor won't be interested until a solidly proven phase lll trial is complete. Who knows, perhaps there will be follow up phase lll trials required. But based on what Don said we won't see any economic action on RVX until Q4 2018 unless an opportunistic suitor decides to get control of RVX before that time. There is alot of IP and 2000+ compounds, the blood bank, a lead on epigenetics in CVD, etc that provides huge opportunities for a suitor with the right risk profile.
Regarding the futility analysis on BETonMACE probably to be announced in Q3/4 2017 viewed in the context of share price impact if it fails the stock will probably be back down to $0.10 or less (and I'll be buying). The company won't be dead but certainly on life support with key people in place to pull the plug, as we've all noted. So my perspective as a long term holder I'll be looking for any clue along the way such as new learning on the science side, more DSMB reports, licensing deals (the licensee will have studied RVX thoroughly), etc and if the stock increases before the futility analysis I'll take some profit and retain a large base of shares at no cost. If the futility analysis passes it does not mean that BETonMACE will succeed. Remember it is a 3 point MACE definition and have scant evidence at best that apabetalone will pass that test!
However, if apabetalone does pass the futility analysis, as I understand it, this means that it still meets the safety standards at that point AND there is enough evidence regarding efficacy to continue the trial (with the associated costs) as opposed to shutting it down and saving money. (please correct me if I am wrong on this). This could elavate the share price, perhaps, up to the $5.00 +++ level that it should be at now based on analysts reports.
Anyway, unless an interesting suitor comes along in the interim period we have a very long wait on RVX. Interest could be triggered by renal, orphan trials, etc. Let's hope.
I must have my rambling disease treated in 2017. Perhaps apabetalone will help :) !!!
GLTA
Toinv